Tinnitus - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Tinnitus - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in Tinnitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Tinnitus: Overview
Tinnitus is commonly described as a ringing in the ears, but it also can sound like roaring, clicking, hissing, or buzzing. It may be soft or loud, high pitched or low pitched. Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. The most common associated symptoms or subjective discomforts involve concentration difficulties, insomnia, and decreased speech discrimination. Tinnitus does not represent a disease itself but instead is a symptom of a variety of underlying diseases. Otologic causes include noise-induced hearing loss, presbycusis, otosclerosis, otitis, impacted cerumen, sudden deafness, Meniere's disease, and other causes of hearing loss. The most effective treatment for tinnitus is to work on the underlying cause. The underlying cause can be treatable by medical and/or surgical treatment. Approaches for tinnitus management and treatment include medications, vitamin therapy, biofeedback, hypnosis, electrical stimulation, relaxation therapy, counselling, habituation therapies, tinnitus retraining therapy [TRT], cognitive behavioural therapy [CBT], tinnitus maskers and hearing aid.
'Tinnitus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Tinnitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tinnitus Emerging Drugs
Further product details are provided in the report
Tinnitus: Therapeutic Assessment
This segment of the report provides insights about the different Tinnitus drugs segregated based on following parameters that define the scope of the report, such as:
Tinnitus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Tinnitus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tinnitus drugs.
Tinnitus Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Tinnitus - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in Tinnitus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Tinnitus: Overview
Tinnitus is commonly described as a ringing in the ears, but it also can sound like roaring, clicking, hissing, or buzzing. It may be soft or loud, high pitched or low pitched. Tinnitus represents one of the most common and distressing otologic problems, and it causes various somatic and psychological disorders that interfere with the quality of life. The most common associated symptoms or subjective discomforts involve concentration difficulties, insomnia, and decreased speech discrimination. Tinnitus does not represent a disease itself but instead is a symptom of a variety of underlying diseases. Otologic causes include noise-induced hearing loss, presbycusis, otosclerosis, otitis, impacted cerumen, sudden deafness, Meniere's disease, and other causes of hearing loss. The most effective treatment for tinnitus is to work on the underlying cause. The underlying cause can be treatable by medical and/or surgical treatment. Approaches for tinnitus management and treatment include medications, vitamin therapy, biofeedback, hypnosis, electrical stimulation, relaxation therapy, counselling, habituation therapies, tinnitus retraining therapy [TRT], cognitive behavioural therapy [CBT], tinnitus maskers and hearing aid.
'Tinnitus - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Tinnitus pipeline landscape is provided which includes the disease overview and Tinnitus treatment guidelines. The assessment part of the report embraces, in depth Tinnitus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tinnitus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Tinnitus R&D. The therapies under development are focused on novel approaches to treat/improve Tinnitus.
This segment of the Tinnitus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Tinnitus Emerging Drugs
- AM-101: Auris Medical
- OTO-313: Otonomy
Further product details are provided in the report
Tinnitus: Therapeutic Assessment
This segment of the report provides insights about the different Tinnitus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Tinnitus
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Tinnitus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Tinnitus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Tinnitus drugs.
Tinnitus Report Insights
- Tinnitus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Tinnitus drugs?
- How many Tinnitus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Tinnitus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Tinnitus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Tinnitus and their status?
- What are the key designations that have been granted to the emerging drugs?
- Auris Medical
- Sound Pharmaceuticals
- Otonomy
- Knopp Biosciences
- Otologic Pharmaceutics
- Decibel Therapeutics
- AM-101
- Ebselen
- OTO-313
- AM 102
- Research programme: potassium channel activators
- NHPN-1010
- DB-XX5
Introduction
Executive Summary
Tinnitus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tinnitus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tinnitus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tinnitus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Late Stage Products (Phase III)
Comparative Analysis
AM-101: Auris Medical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
OTO-313: Otonomy
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: potassium channel activators - Knopp Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Tinnitus Key Companies
Tinnitus Key Products
Tinnitus- Unmet Needs
Tinnitus- Market Drivers and Barriers
Tinnitus- Future Perspectives and Conclusion
Tinnitus Analyst Views
Tinnitus Key Companies
Appendix
Executive Summary
Tinnitus: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Tinnitus – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Tinnitus companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Tinnitus Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Late Stage Products (Phase III)
Comparative Analysis
AM-101: Auris Medical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
OTO-313: Otonomy
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
Comparative Analysis
Research programme: potassium channel activators - Knopp Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Tinnitus Key Companies
Tinnitus Key Products
Tinnitus- Unmet Needs
Tinnitus- Market Drivers and Barriers
Tinnitus- Future Perspectives and Conclusion
Tinnitus Analyst Views
Tinnitus Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Tinnitus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Tinnitus
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Tinnitus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Tinnitus
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products